Related Experiment Videos

Obstetric implications of activated protein C resistance and factor V Leiden mutation

R B Gherman1, T M Goodwin

  • 1Division of Maternal/Fetal Medicine, Portsmouth Naval Hospital, Virginia 23708-2197, USA. ghermtoo@aol.com

Insights

Activated protein C resistance (APCR), often due to the factor V Leiden mutation, is a major genetic risk for blood clots. Emerging research links APCR to pregnancy complications like hypertensive disorders and placental issues.

Area of Science:

  • Hematology
  • Genetics
  • Obstetrics

Background:

  • Activated protein C resistance (APCR) is the most common genetic risk factor for thromboembolic disease.
  • Over 90% of APCR cases stem from the factor V Leiden mutation.
  • The factor V Leiden mutation involves a specific gene substitution (G1691A) leading to an amino acid change (Q506R).

Purpose of the Study:

  • To summarize the significance of APCR and the factor V Leiden mutation.
  • To highlight the association between APCR/factor V Leiden and adverse pregnancy outcomes.

Main Methods:

  • Literature review and synthesis of existing research findings.
  • Analysis of genetic data related to factor V Leiden mutation.
  • Epidemiological data review on pregnancy complications.

Main Results:

  • Activated protein C resistance is a leading identifiable cause of thrombosis.
  • The factor V Leiden mutation is the primary genetic cause of APCR.
  • Evidence suggests a link between APCR/factor V Leiden and conditions such as hypertensive disorders of pregnancy, miscarriage, placental infarction, and abruption.

Conclusions:

  • Activated protein C resistance, particularly due to factor V Leiden, is a critical factor in thrombosis.
  • Further investigation into the APCR-pregnancy complication link is warranted.
  • Understanding this genetic risk is vital for managing thromboembolic and obstetric conditions.

Related Concept Videos